Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Revolutionizing diabetes management by combining in silico models and AI control for vagus neuroprostheses

Project description

Automated vagus nerve stimulation to control circulating blood glucose levels

The body’s cells use glucose to make energy. Diabetes is characterised by impaired regulation of circulating blood glucose levels which is difficult to treat effectively. An automated approach that adapts to patients’ changing conditions is urgently needed. Vagus nerve stimulation (VNS) may modulate glucose metabolism. However, because the vagus nerve innervates many internal organs, careful investigation of nerve-implant interaction and the circuits stimulated is required. The ERC-funded DiabetManager project aims to develop the first VNS neuroprosthesis for personalised regulation of glucose levels in diabetics. Work will include development of a vagus nerve in silico model, models-driven interface design, AI-based stimulation policies, animal experiments, and human trials.

Objective

Diabetes is a major world health problem, approaching epidemic proportions and causing long term health damages due to inappropriate blood glucose regulation. Pharmacological therapies are limited by numerous side effects (as renal insufficiency or heart failure) and dose management issues. Their efficacy is also hindered by often problematic, patients’ compliance. This results in an unmet need for automatized, closed-loop glucose metabolism regulation, adaptable to variable patients’ conditions. Vagus nerve (VN) is a major component of the autonomous nervous system innervating internal organs, and its electrical stimulation showed preliminary results in modulating glucose metabolism. However, underlying mechanisms remain unknown, posing a high-risk to its feasibility, and could lead to indiscriminate stimulation causing multiple side effects (compromising breathing or heart rate). Fine glucose regulation cannot be achieved without better understanding of nerve-implant interaction and circuits stimulated by VNS. I aim to fill present scientific gaps by developing the first VNS neuroprosthesis for personalized closed-loop-regulation of glucose levels in diabetics. This results in a significant challenge: defining stimulation policies able to selectively block or activate specific neural pathways, while counteracting metabolic shifts and implant-nerve alterations. To that aim I will exploit models-driven interface design and AI-based stimulation policies. Animal experiments will investigate the physiological responses to optimal policies, maximising glucose regulation while minimizing adverse events, inspecting both cervical and abdominal VNS. Optimal VNS will be validated in human trials achieving device assessment in patients. DiabetManager will shed light on the underlying mechanisms of VNS-mediated glucose metabolism control, while providing versatile VN in-silico model, unprecedent AI-architecture for its adaptive stimulation, and disruptive health treatment.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

You need to log in or register to use this function

Host institution

UNIVERSIDAD POMPEU FABRA
Net EU contribution
€ 1 999 201,00
Address
PLACA DE LA MERCE, 10-12
08002 Barcelona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 999 201,00

Beneficiaries (1)